Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	14.56	9.5	8.95	14.7	4.34
Revenue Growth (YoY)	53.24%	6.19%	-39.16%	238.70%	137.73%
Cost of Revenue	0.15	0.33	-0.67	0.73	-1.43
Gross Profit	14.41	9.17	9.62	13.98	2.92
Selling, General & Admin	18.46	18.17	17.3	22.51	18.21
Research & Development	17.73	12.47	15.71	13.99	33.91
Other Operating Expenses	14.84	-	-	-	-
Total Operating Expenses	51.03	30.64	33.01	36.5	52.13
Operating Income	-36.62	-21.48	-24.73	-22.52	-49.21
Interest Income	1.69	1.72	1.63	0.83	0
Other Non-Operating Income (Expense)	-33.72	1.18	-0.18	-4.12	4.45
Total Non-Operating Income (Expense)	-32.03	2.9	1.45	-3.29	4.46
Pretax Income	-68.65	-18.58	-23.28	-25.81	-43.27
Provision for Income Taxes	-5.28	-	-1.8	0.54	-
Net Income	-63.53	-18.61	-21.49	-26.27	-43.02
Minority Interest in Earnings	0.17	0.03	0.01	-0.08	-0.25
Net Income to Common	-63.53	-18.61	-21.49	-26.27	-43.02
Shares Outstanding (Basic)	230	200	173	170	165
Shares Outstanding (Diluted)	230	200	173	170	165
Shares Change (YoY)	14.95%	15.94%	1.69%	3.22%	9.64%
EPS (Basic)	-0.28	-0.09	-0.12	-0.15	-0.26
EPS (Diluted)	-0.28	-0.09	-0.12	-0.15	-0.26
Free Cash Flow	-19.44	-23.66	-29.24	0.65	-23.9
Free Cash Flow Per Share	-0.08	-0.12	-0.17	0.00	-0.15
Gross Margin	99.00%	96.48%	107.50%	95.05%	67.15%
Operating Margin	-251.57%	-226.11%	-276.50%	-153.17%	-1133.63%
Profit Margin	-435.33%	-195.62%	-240.12%	-179.24%	-996.77%
FCF Margin	-133.56%	-249.05%	-326.89%	4.39%	-550.59%
EBITDA	-35.92	-20.87	-24.04	-21.79	-48.34
EBITDA Margin	-246.77%	-219.70%	-268.76%	-148.22%	-1113.52%
EBIT	-36.62	-21.48	-24.73	-22.52	-49.21
EBIT Margin	-251.57%	-226.11%	-276.50%	-153.17%	-1133.63%
Effective Tax Rate	7.69%	0.00%	7.74%	-2.10%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q